Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Infinity signs deal with J&JPRD for small-molecule drugs

Executive Summary

In its second deal in just as many days, Infinity Pharmaceuticals (small-molecule cancer therapeutics) has signed an agreement covering the use of its compound collection. This small-molecule deal gives Johnson & Johnson Pharmaceutical R&D a non-exclusive license to the library against which J&JPRD can screen multiple targets and perform chemistry activities to identify drug leads.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register